Examples of investigational bsAbs for anti-cancer immunotherapy include CD28/PSMA bsAb for prostate cancer from Regeneron, CD3/CLEC12A bsAb for liquid tumor from Merus N.V., programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) bsAbs from Eli Lilly and Innovent Biologics for advanced solid tumors, and EGFR/c-Met bsAb from Shanghai EpimAb Biotherapeutics for advanced solid tumors. Here, PDCD1 is linked to prostate carcinoma.